RxDoctor Payments Data

Yogesh Kiranraj Sanghvi

Nephrology · Lakewood Ranch, FLNPI 1184870891

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $595 of the $699 with a category attached, or 85.1%. It is spread thinly across 14 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $175 and has fallen 55.3% since, to $78 in 2025. That places this record below the midpoint for nephrology clinicians in FL, where the typical reported total is $1,407.

$699in general payments, 2019–2025

Across 26 payments — averaging $26.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$159
  • Baxter Healthcare$96
  • AstraZeneca$96
  • Fresenius USA Marketing, Inc.$71
  • Amgen$66
  • Bayer$54
  • plus $158 from 8 others

What the payments were for

  • Food & beverage$59585%
  • Education$10415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$699 in reported general payments places this provider in the 35th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida →

Medicare billing

Part B allowed, 2024
$176,518
Medicare patients
308
Services billed
1,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex16$22,368
FarxigaDapagliflozin Propanediol29$20,595
Sevelamer Carbonate37$6,770
Lanthanum Carbonate14$6,295
Bumetanide63$2,710
Midodrine Hcl19$1,822
Calcium Acetate16$1,590
Potassium Chloride46$1,233
Nifedipine ErNifedipine44$1,021
Potassium Citrate ErPotassium Citrate15$806
Carvedilol98$695
Hydralazine Hcl66$675
Amlodipine Besylate94$647
Furosemide117$610
Lisinopril89$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$96$20,59529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 756 nephrology providers in Florida.

Other nephrology in Lakewood Ranch

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →